Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Allarity Therapeutics Inc

Healthcare US ALLR

1.3201USD
-0.0399(2.93%)

Last update at 2026-06-23T15:03:00Z

Day Range

1.301.36
LowHigh

52 Week Range

0.772.06
LowHigh

Fundamentals

  • Previous Close 1.36
  • Market Cap19.77M
  • Volume38761
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.59600M
  • Revenue TTM0.32M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 0.32M
  • Diluted EPS TTM-0.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.23100M -24.89600M -11.81800M -17.57900M -26.51500M
Minority interest - - - - 0.00000M
Net income -11.23100M -24.51500M -11.90100M -16.05800M -26.64800M
Selling general administrative 6.32M 11.44M 10.03M 9.96M 12.36M
Selling and marketing expenses - - - - -
Gross profit 0.32M -0.00900M -0.03700M - -
Reconciled depreciation -0.01300M 0.00900M 0.03M 0.06M 0.11M
Ebit -11.03300M -24.24300M -11.32000M -34.46300M -26.55600M
Ebitda -11.04600M -24.23400M -11.28300M -16.80200M -28.27100M
Depreciation and amortization -0.01300M 0.00900M 0.04M 17.66M -1.71500M
Non operating income net other - - - 16.88M -
Operating income -12.60500M -27.24100M -17.12900M -34.46300M -26.55600M
Other operating expenses 12.93M 27.24M 17.13M 16.89M 26.56M
Interest expense 0.18M 0.65M 0.50M 0.22M 0.50M
Tax provision 0.00000M -0.38100M -0.30300M -1.52100M 0.13M
Interest income 0.80M 0.53M 0.03M 0.03M -
Net interest income 0.62M -0.12000M -0.35400M -0.19300M -1.84600M
Extraordinary items - - - - -
Non recurring - - - 17.57M -
Other items - - - - -
Income tax expense - -0.38100M 0.08M -1.52100M 0.13M
Total revenue 0.32M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 12.93M 27.24M 17.13M 16.89M 26.56M
Cost of revenue - 0.00900M 0.04M - -
Total other income expense net 1.37M 2.35M 5.31M 16.88M 0.04M
Discontinued operations - - - - -
Net income from continuing ops -11.23100M -24.51500M -13.01700M -16.05800M -26.64800M
Net income applicable to common shares - - - -21.05100M -26.64800M
Preferred stock and other adjustments - - - 4.99M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.26M 22.65M 11.86M 14.54M 49.63M
Intangible assets - - 9.87M 9.55M 28.14M
Earning assets - - - - -
Other current assets 2.35M 0.58M 0.86M 2.07M 1.50M
Total liab 8.43M 10.84M 14.61M 12.65M 30.85M
Total stockholder equity 9.83M 11.81M -2.75100M 1.89M 18.78M
Deferred long term liab - - - 1.43M -
Other current liab 2.67M 5.23M 4.39M 2.32M 11.27M
Common stock 0.00300M 0.00100M - 0.00200M 0.81M
Capital stock 0.00300M 0.00100M 1.74M 2.00M 1.44M
Retained earnings -130.19700M -118.96600M -94.45100M -82.55000M -66.49200M
Other liab - - - 0.35M 9.14M
Good will - - - - -
Other assets - - - - -
Cash 14.69M 19.53M 0.17M 2.03M 19.55M
Cash and equivalents - - - - -
Total current liabilities 8.43M 10.84M 14.17M 11.22M 20.72M
Current deferred revenue - - 0.06M - 8.65M
Net debt -13.28700M -18.18300M 1.13M 1.71M -18.46900M
Short term debt 1.40M 1.35M 1.30M 2.65M 0.10M
Short long term debt 1.40M 1.35M 1.30M 2.64M -
Short long term debt total 1.40M 1.35M 1.30M 3.73M 1.09M
Other stockholder equity 141.04M 131.13M 90.37M 83.16M 84.43M
Property plant equipment - - - 0.02M 0.09M
Total current assets 17.93M 22.34M 1.97M 4.97M 21.05M
Long term investments - - - - 0.35M
Net tangible assets - - - -7.65900M -9.98300M
Short term investments - 0.07M - 0.00000M -
Net receivables 0.90M 2.23M 0.95M 0.87M 1.34M
Long term debt - - - 1.08M 0.98M
Inventory - - - - -1.34500M
Accounts payable 4.28M 4.18M 8.42M 6.25M 0.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.02100M -0.35400M -0.41100M -0.72100M -0.60000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00200M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -82.55000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.00600M 0.35M
Deferred long term asset charges - - - - -
Non current assets total 0.33M 0.31M 9.89M 9.58M 28.58M
Capital lease obligations - - 0.00000M 0.00800M 0.11M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.29800M -0.01800M 0.79M 1.00M
Change to liabilities - - - 1.37M -1.31100M
Total cashflows from investing activities -0.00800M -0.29800M - 0.79M 1.00M
Net borrowings 0.00000M 0.00000M -2.64900M 1.00M 0.97M
Total cash from financing activities 10.65M 36.79M 10.99M -1.31100M 33.82M
Change to operating activities - - - -6.51600M 6.87M
Net income -11.23100M -24.51500M -11.90100M -16.05800M -26.64800M
Change in cash -4.84600M 19.37M -1.86300M -17.52600M 19.26M
Begin period cash flow 19.53M 0.17M 2.03M 19.55M 0.30M
End period cash flow 14.69M 19.53M 0.17M 2.03M 19.55M
Total cash from operating activities -14.82000M -17.35200M -12.74500M -16.81700M -15.05000M
Issuance of capital stock 13.84M 40.29M 18.05M 0.00000M 32.12M
Depreciation -0.01300M 0.00900M 0.04M 0.06M 0.11M
Other cashflows from investing activities -0.00800M -0.29800M - 0.81M -
Dividends paid - - 10.99M 1.51M -
Change to inventory - - - - -
Change to account receivables -0.09600M 0.04M -0.02600M - 0.00000M
Sale purchase of stock -3.19000M -3.50000M -6.65400M -1.51100M -
Other cashflows from financing activities 10.65M -0.56200M -3.25100M 0.20M 4.64M
Change to netincome - - - 16.52M 5.92M
Capital expenditures 0.00800M 0.30M 0.00000M 0.02M 0.02M
Change receivables - - - - -
Cash flows other operating - - - -18.70500M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -17.33700M -
Change in working capital -5.68000M 0.06M 3.35M -0.32800M 5.57M
Stock based compensation 0.48M 0.07M -0.07100M 1.75M 6.37M
Other non cash items -9.14000M 7.47M -4.25900M -0.63100M -0.46600M
Free cash flow -14.82800M -17.65000M -12.74500M -16.83500M -15.05000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALLR
Allarity Therapeutics Inc		 -0.0399 2.93% 1.32 - - 61.79 2.03 20.77 -0.0842
NVO
Novo Nordisk A/S		 1.15 2.51% 47.03 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.41 0.30% 468.20 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.50 1.06% 619.00 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Allarity Therapeutics Inc

24 School Street, Boston, MA, United States, 02108

Key Executives

Name Title Year Born
Mr. James G. Cullem J.D. Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director 1969
Dr. Marie Foegh DrSc, M.D. Chief Medical Officer 1944
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. Co-Founder 1955
Dr. Steen Meier Knudsen Ph.D. Founder & Chief Scientific Officer 1961
Mr. Thomas H. Jensen Founder, Sr. VP of Investor Relations & Director 1978
Mr. Claus Frisenberg Pedersen Chief Commercial Officer 1972
Ms. Joan Brown Interim CFO & Director of Financial Reporting 1953
Ms. Annie Rasmussen Chief of Clinical Operations 1957
Mr. Thomas H. Jensen Founder, CEO, Senior VP of Investor Relations & Director 1978
Ms. Joan Y. Brown Interim CFO 1954

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.